Biochemical Reagent
-
BA6617 VanzacaftorSummary: Vanzacaftor (VX-121) is a new orally effective corrective agent. - BA6618 NJH-2-057Summary: A deubiquitinase covalent ligand-linked lumacaftor conjugate that stabilizes mutant proteins in cells.
- BA6619 BamocaftorSummary: Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance modulator corrector designed to restore protein function.
- BA6620 NavocaftorSummary: Navocaftor (GLPG3067) as a cystic fibrosis transmembrane modulator.
- BA6621 CavosonstatSummary: Cavosonstat (N91115) is an orally active inhibitor.
- BA6622 GalicaftorSummary: An effective, orally active transmembrane conductance modulator corrector for cystic fibrosis
-
BA6623 SRI-37240Summary: SRI-37240 is a potent early termination codon inhibitor. - BA6624 IcenticaftorSummary: Icenticaftor (QBW251) is an orally active channel enhancer.
- BA6625 NJH-2-056Summary: NJH-2-056 is a deubiquitinase-targeting chimera with linked recruitment factor EN523 and chaperone protein lumacaftor.
- BA6626 KobusinSummary: Kobusin was isolated from a double epoxy lignan.